Journal Description
International Journal of Translational Medicine
International Journal of Translational Medicine
is an international, peer-reviewed, open access journal on major advances in both experimental and clinical medicine, with a particular emphasis on translational research published quarterly online by MDPI.
- Open Access— free for readers, with article processing charges (APC) paid by authors or their institutions.
- Rapid Publication: manuscripts are peer-reviewed and a first decision is provided to authors approximately 24 days after submission; acceptance to publication is undertaken in 3.4 days (median values for papers published in this journal in the first half of 2024).
- Recognition of Reviewers: APC discount vouchers, optional signed peer review, and reviewer names published annually in the journal.
- IJTM is a companion journal of Biomedicines.
Latest Articles
Shaping the Landscape of Lung Cancer: The Role and Therapeutic Potential of Matrix Metalloproteinases
Int. J. Transl. Med. 2024, 4(4), 661-679; https://doi.org/10.3390/ijtm4040046 - 22 Nov 2024
Abstract
►
Show Figures
Lung cancer is a leading cause of cancer-related mortality worldwide, characterized by its aggressive nature and poor prognosis. Matrix metalloproteinases (MMPs), a family of zinc-dependent endopeptidases, play a pivotal role in the progression of lung cancer. They contribute to tumor invasion, metastasis, angiogenesis,
[...] Read more.
Lung cancer is a leading cause of cancer-related mortality worldwide, characterized by its aggressive nature and poor prognosis. Matrix metalloproteinases (MMPs), a family of zinc-dependent endopeptidases, play a pivotal role in the progression of lung cancer. They contribute to tumor invasion, metastasis, angiogenesis, and the modulation of the tumor microenvironment by degrading extracellular matrix components and regulating various cellular signaling pathways. Elevated levels of specific MMPs, such as MMP-2, MMP-9, and MMP-14, have been associated with advanced disease stages and reduced survival rates. As such, MMPs have emerged as valuable biomarkers for the diagnosis, prognosis, and prediction of treatment responses in lung cancer. This review aims to provide a comprehensive overview of the current understanding of MMPs in lung cancer, highlighting their diagnostic and prognostic significance, as well as their potential as therapeutic targets. Despite the initial setbacks in developing broad-spectrum MMP inhibitors, recent advancements have spurred interest in more selective inhibitors that minimize off-target effects and enhance therapeutic efficacy. Furthermore, combining MMP-targeted therapies with conventional treatments, such as chemotherapy and immunotherapy, holds promise for improving clinical outcomes. Future research directions include exploring novel MMP inhibitors, understanding the regulatory mechanisms of MMP activity, and integrating MMP biomarkers into personalized medicine approaches. As the field progresses, targeting MMPs may offer new therapeutic avenues and improve the prognosis for lung cancer patients, making this a promising area of investigation.
Full article
Open AccessReview
Tissue Biomarkers in Gastric Cancer Treatment: Present and Future
by
Giulia Airò, Virginia Agnetti, Fabiana Pratticò, Marianna Peroni, Simona Bui, Giovanni Mura, Maria Urbanowicz-Nijaki, Eleonora Lai, Marco Puzzoni, Fabiana Contu, Nerina Denaro, Mario Scartozzi, Cinzia Solinas and Chiara Tommasi
Int. J. Transl. Med. 2024, 4(4), 640-660; https://doi.org/10.3390/ijtm4040045 - 22 Nov 2024
Abstract
The aggressive nature of gastric cancer often leads to late diagnosis and poor prognosis. Chemotherapy and the more recently added immunotherapy remain key treatments for this disease. Several studies have focused on identifying tissue biomarkers with prognostic and/or predictive roles and therefore the
[...] Read more.
The aggressive nature of gastric cancer often leads to late diagnosis and poor prognosis. Chemotherapy and the more recently added immunotherapy remain key treatments for this disease. Several studies have focused on identifying tissue biomarkers with prognostic and/or predictive roles and therefore the therapeutic options are rapidly growing. In this narrative review, we summarize the major tissue biomarkers routinely assessed in clinical practice. In addition, we focus on new evidence about emerging tissue biomarkers that could have a predictive role in future therapeutic approaches and also on the potential role of liquid biopsy in this neoplasm.
Full article
Open AccessCase Report
The Successful and Safe Real-Time TDM-Guided Treatment of Invasive Pulmonary Aspergillosis Using Isavuconazole Administered by Enteral Tube
by
Álvaro Corral Alaejos, Jose Jiménez Casaus, Ángel López Delgado and Aranzazu Zarzuelo Castañeda
Int. J. Transl. Med. 2024, 4(4), 631-639; https://doi.org/10.3390/ijtm4040044 - 22 Nov 2024
Abstract
►▼
Show Figures
Background: Invasive aspergillosis (IA) is an opportunistic infection that affects immunocompromised patients. While voriconazole is commonly used for IA treatment, it presents the risk of drug interactions, particularly in patients on polytherapy. Isavuconazole may serve as a safer alternative with fewer interactions. However,
[...] Read more.
Background: Invasive aspergillosis (IA) is an opportunistic infection that affects immunocompromised patients. While voriconazole is commonly used for IA treatment, it presents the risk of drug interactions, particularly in patients on polytherapy. Isavuconazole may serve as a safer alternative with fewer interactions. However, the use of isavuconazole is typically limited to the parenteral route for patients without access to the enteral route, due to recommendations against tablet handling for enteral administration. The objective of this study was to evaluate the suitability of isavuconazole administration via an enteral tube, by therapeutic drug monitoring of isavuconazole plasma concentrations. Methods: This case study examines a patient with diffuse large B-cell lymphoma who was diagnosed with IA and treated with isavuconazole via an enteral tube. Therapeutic pharmacokinetic monitoring of isavuconazole plasma concentrations was performed to assess the feasibility and safety of enteral administration. Results: The results show that isavuconazole concentrations were maintained within the therapeutic range when administered via an enteral tube. No significant deviations in plasma concentration were noted during the monitoring period. Conclusions: Administering isavuconazole through an enteral tube is a safe and viable alternative for patients that are unable to receive the drug via the oral route. Therapeutic monitoring of plasma concentrations is recommended to ensure proper dosing and efficacy.
Full article
Figure 1
Open AccessArticle
Role of Circulating X-Chromosome Inactivation and Xist as Biomarkers in Female Carriers of Fabry Disease
by
Salvatore Rossi, Arcangelo Fargnoli, Daniele Di Natale, Gianmarco Dalla Zanna, Antonio Funcis, Federica Re, Vincenza Gragnaniello, Elena Verrecchia, Alberto Burlina, Elisabetta Tabolacci and Gabriella Silvestri
Int. J. Transl. Med. 2024, 4(4), 618-630; https://doi.org/10.3390/ijtm4040043 - 21 Nov 2024
Abstract
Background: Fabry Disease (FD) is an X-linked lysosomal disease, in which, unlike other X-linked disorders, most female carriers manifest signs or symptoms for unknown reasons. Objectives: Herein, we aimed to test the potential role of X-chromosome inactivation (XCI) in leukocytes as a prognostic
[...] Read more.
Background: Fabry Disease (FD) is an X-linked lysosomal disease, in which, unlike other X-linked disorders, most female carriers manifest signs or symptoms for unknown reasons. Objectives: Herein, we aimed to test the potential role of X-chromosome inactivation (XCI) in leukocytes as a prognostic biomarker of disease in FD female carriers. Moreover, we explored if levels of X-inactive-specific transcript (Xist), a long non-coding RNA driving XCI, were detectable in the leukocytes of FD female carriers. Methods: We tested the XCI pattern in leukocytes on 33 consecutive females carrying pathogenic GLA variants. Disease severity was defined using the Mainz Severity Score Index (MSSI). Xist levels in leukocytes were assessed by real-time PCR and compared to the levels of 22 controls. Results: XCI was obtained for 31 female patients, finding 16 skewed (51.6%) individuals. Global MSSI did not differ in skewed vs. non-skewed FD carriers. In skewed FD females, the renal function and mean cardiologic MSSI subscore were significantly worse, and systemic arterial hypertension was more frequent. Xist levels detected in leukocytes were similar between female patients and controls, and did not differ by phenotype or XCI status. Conclusions: A skewed XCI pattern in leukocytes may represent a prognostic biomarker of worse renal and cardiac outcomes in female FD carriers.
Full article
Open AccessReview
Novelty Seeking in Parkinson’s Disease: A Candidate Biomarker for Cognitive Changes
by
Kyle Paulk and Lee E. Neilson
Int. J. Transl. Med. 2024, 4(4), 608-617; https://doi.org/10.3390/ijtm4040042 - 10 Nov 2024
Abstract
►▼
Show Figures
Background: Parkinson’s disease (PD) is a common neurodegenerative disorder characterized by motor impairments, cognitive decline, and affective changes. Beyond the well-described motor symptoms, neuropsychiatric symptoms play a crucial role in PD disability burden. Novelty seeking, a trait extensively studied within various models of
[...] Read more.
Background: Parkinson’s disease (PD) is a common neurodegenerative disorder characterized by motor impairments, cognitive decline, and affective changes. Beyond the well-described motor symptoms, neuropsychiatric symptoms play a crucial role in PD disability burden. Novelty seeking, a trait extensively studied within various models of personality, may influence the manifestation of these non-motor symptoms. Methods: A narrative review of articles determined relevant by the author(s) was undertaken. Results: The literature indicates that PD patients typically exhibit low novelty seeking initially. However, dopaminergic therapies can increase novelty-seeking behaviors, sometimes leading to impulse control disorders (ICD). Studies using the Temperament and Character Inventory (TCI) suggest a complex interplay between disease state, medication, and baseline personality, which is not fully elucidated. High novelty seeking scores predict a higher risk of ICDs, yet they also correlate with a more benign clinical phenotype and improved quality of life post-DBS surgery. Conclusions: Novelty seeking is a significant trait in PD, influencing non-motor symptoms and treatment responses. Understanding its neurobiological basis and clinical implications could lead to better diagnostic and therapeutic strategies through the use of objective, practical tools for disease monitoring, individualized therapy, and pharmacological development.
Full article
Figure 1
Open AccessArticle
Growth Promotion and Economic Benefits of the Probiotic Lactiplantibacillus plantarum in Calves
by
Kazumasa Osawa, Saya Taharaguti, Chiaki Ito, Tadashi Takino and Katsuro Hagiwara
Int. J. Transl. Med. 2024, 4(4), 595-607; https://doi.org/10.3390/ijtm4040041 - 31 Oct 2024
Abstract
►▼
Show Figures
Objectives: Various measures have been attempted to prevent infectious diseases in calves, such as environmental improvement and vaccine administration. Probiotics are commonly used to improve the body condition of newborn calves and prevent disease. In our previous research, Lactiplantibacillus plantarum RGU-LP1 (LP1)
[...] Read more.
Objectives: Various measures have been attempted to prevent infectious diseases in calves, such as environmental improvement and vaccine administration. Probiotics are commonly used to improve the body condition of newborn calves and prevent disease. In our previous research, Lactiplantibacillus plantarum RGU-LP1 (LP1) suppressed the expression of inflammatory cytokines in PBMCs of cattle fed it in the diet. In this study, we evaluated the effect of LP1 on the weights and number of treatments of the calves. Methods: Twenty-six one-week-old Holstein bull calves were divided into two groups (thirteen each), the LP1 group (LP1-treated) and the CN group (no LP1 fed), and tested as follows. The LP1 group was fed lyophilized LP1 (109 CFU/head/day) in milk replacer for 40 days. The CN group was fed the same diet only. Calves were followed for 63 days. The average treatment costs for the LP1 during the period were recorded. Feces and blood were collected from each calf during this period. Feces were examined for gut microbiota, and blood for immune assay and cytokine gene expression. Results: The LP1-treated group showed a decrease in disease incidence and an increase in body weights compared to controls. The average treatment cost during the observation period was significantly reduced compared to the CN group. The expression of TGFβ and IL10, inhibitory cytokines of inflammation, was significantly increased. The simultaneous expression of this set of inhibitory molecules resulted in low serum IL1β levels during the growth period. Conclusions: The Th1-type cytokine IFNγ was also significantly increased in LP1-treated calves. By reducing the amount of disease treatments and increasing dairy gain, LP1 is effective in preventing infectious diseases in calves. In addition, the increase in IFNγ by LP1 indicates improved Th1-type immunity in calves. These results show that LP1 has effects on the regulated inflammatory response and growth of calves.
Full article
Figure 1
Open AccessArticle
Differences in Prevalence of Colorectal Carcinoma by Gender and Marital Status and Expression of DNA Mismatch Repair Proteins
by
Peilin Zhang, Omid Bakhtar, Chris Wixom, Brian Cox, John Lee, Saha Sadeghi, Aidan Clement, Lana Kabakibi and Madeleine Schwab
Int. J. Transl. Med. 2024, 4(3), 584-594; https://doi.org/10.3390/ijtm4030040 - 23 Sep 2024
Abstract
Background: The effect of gender dimorphism and marital status on colorectal cancer mortality have been previously documented, but the relationship between these factors and DNA mismatch repair protein (MMRP) expression status is unknown. Methods: Colectomy specimens were reviewed retrospectively for patients between 2018
[...] Read more.
Background: The effect of gender dimorphism and marital status on colorectal cancer mortality have been previously documented, but the relationship between these factors and DNA mismatch repair protein (MMRP) expression status is unknown. Methods: Colectomy specimens were reviewed retrospectively for patients between 2018 and 2023, with demographics including race/ethnicity, gender, marital status, faith, body mass index, pathologic staging, and MMRP expression status. Statistical analyses were performed by using baseline characteristics tables and various programs in the R package. Results: A total 1018 colectomies were reviewed, and the tumor stages were significantly higher in the right colon (stage 3 and 4) than in the left colon and rectosigmoid colon (p < 0.01). Marital status was significantly associated with patients’ gender, age, tumor size, and tumor stages (all p < 0.01). MMRP status was available in 775 cases, with 139 (17.9%) MMRP-deficient and 636 (82%) MMRP-proficient. MMRP deficiency was significantly associated with older female patients, larger tumor sizes, higher tumor stages, higher histologic grades, and was more common in the right colon (all p < 0.01). In addition, MMRP deficiency was statistically associated with a higher percentage of divorced and widowed patients (p < 0.01). Multivariate linear regression analysis revealed a persistent association of MMRP deficiency with tumor size, tumor grade, tumor stage, and nodal metastasis, but the associations with gender and marital status no longer existed. Conclusions: The differences in prevalence of CRC by gender and marital status and tumor MMRP status illustrate the importance of these factors on tumor stages and nodal metastasis but these associations are more complex with other confounding factors.
Full article
(This article belongs to the Collection Feature Papers in International Journal of Translational Medicine)
►▼
Show Figures
Figure 1
Open AccessReview
Non-Invasive In Vivo Bioimaging in Pigs
by
Tomoyuki Abe, Kazuhiro Endo, Yutaka Hanazono and Eiji Kobayashi
Int. J. Transl. Med. 2024, 4(3), 570-583; https://doi.org/10.3390/ijtm4030039 - 18 Sep 2024
Abstract
►▼
Show Figures
Imaging technologies are used to observe the morphology and function of various organs in the body and have become indispensable in a multitude of fields, ranging from basic research to clinical medicine. The luminescence technology based on the luciferin–luciferase reaction has been used
[...] Read more.
Imaging technologies are used to observe the morphology and function of various organs in the body and have become indispensable in a multitude of fields, ranging from basic research to clinical medicine. The luminescence technology based on the luciferin–luciferase reaction has been used in many research fields as an imaging technique, enabling quantitative analysis and detection at high sensitivity. Specifically in gene therapy and cell therapy, it has been developed as an in vivo bioimaging technique mainly for small animal models because of its non-invasive and time-sequential analysis. Currently, translational research using this luminescence imaging technology in pigs for clinical applications is ongoing. In this review, we discuss the progress of these technologies and issues for their clinical application, focusing on pigs, by comparing conventional imaging techniques, including fluorescent probes, with luminescence imaging techniques.
Full article
Figure 1
Open AccessReview
FLASH Radiotherapy Versus Conventional Cancer Therapy: Promises, Paradoxes and Problems
by
Stephen C. Bondy
Int. J. Transl. Med. 2024, 4(3), 559-569; https://doi.org/10.3390/ijtm4030038 - 11 Sep 2024
Abstract
►▼
Show Figures
A novel means of applying radiotherapy in cancer treatment is the application of a radiation dose at a very high intensity for a very short time in FLASH radiotherapy (FLASH-RT). This technique involves the exposure of tumors to >40 Gy/s, usually for less
[...] Read more.
A novel means of applying radiotherapy in cancer treatment is the application of a radiation dose at a very high intensity for a very short time in FLASH radiotherapy (FLASH-RT). This technique involves the exposure of tumors to >40 Gy/s, usually for less than one second. Studies conducted in cell and preclinical models suggest that FLASH-RT seems less damaging to normal tissues from adverse effects relative to the same overall dose of radiation administered in conventional therapy (CONV-RT), which involves the administration of lower levels of radiation repeated intermittently over a protracted period. In contrast, the susceptibility of tumor tissues to FLASH-RT is not diminished relative to CONV-RT. Within solid tumors, both modes of dispensation of radiation produce an equivalent degree of cell damage. The differential treatment between normal and malignant material has been found in isolated tissues, animal studies and, more recently, in clinical trials. However, the classic radiation concept is that high-energy linear transfer radiation (LET) is more damaging than the equivalent total dose of low LET. Thus, the susceptibility of cells should be greater after short-term exposure to high LET. This article discusses the potential reasons that may account for this discrepancy. While the relative protection given to untransformed tissues by FLASH-RT relative to tumor tissue is a major step forward in radiation therapy for cancer, the processes that lie behind this phenomenon are incompletely understood and are considered here.
Full article
Figure 1
Open AccessArticle
Immune Response and Exhaled Breath Profile Changes after Initiation of CFTR Modulator Therapy in Children with CF
by
Koen J. van Aerde, Gerben Ferwerda, Agnieszka Smolinska, Edward Dompeling and Jolt Roukema
Int. J. Transl. Med. 2024, 4(3), 547-558; https://doi.org/10.3390/ijtm4030037 - 27 Aug 2024
Abstract
►▼
Show Figures
Background: In recent years, cystic fibrosis transmembrane regulator (CFTR) modulating therapy has made it possible to treat the underlying pathophysiological defect in children with cystic fibrosis (CF). Response to therapy varies among patients. We investigated the immune responses and exhaled breath profile changes
[...] Read more.
Background: In recent years, cystic fibrosis transmembrane regulator (CFTR) modulating therapy has made it possible to treat the underlying pathophysiological defect in children with cystic fibrosis (CF). Response to therapy varies among patients. We investigated the immune responses and exhaled breath profile changes after the initiation of CFTR modulator therapy to explore their potential as markers of therapy response. Methods: We performed a prospective, longitudinal proof-of-principle study, investigating immune responses and exhaled breath volatile organic component (VOC) profiles prior to and during the initiation of therapy with Lumacaftor/Ivacaftor in a cohort of 17 patients with CF aged 2 to 6 years old. Response to therapy was assessed based on clinical markers and the decrease in sweat chloride. Whole blood stimulation assays were performed at t = 0, 6 and 18 weeks, while VOC analysis was performed at t = 0 and 18 weeks. Results: A pattern of immune reconstitution was found in the first 4 months of therapy. The same pattern was found in responders and non-responders. Exhaled breath VOC profiles were significantly affected by therapy. A trend toward a significant difference was found between responders and non-responders. Conclusions: Pediatric CF patients show a pattern of immune reconstitution after the initiation of CFTR modulating therapy. We hypothesize that this could be explained by the need for a pro-inflammatory profile for a more effective clearance of latent airway pathogens in the initial phase. The exhaled breath profile also clearly changes after the initiation of therapy, indicating the therapy’s influence on airway inflammation and oxidative stress; thus, it might predict the response to therapy.
Full article
Figure 1
Open AccessArticle
Perioperative Buprenorphine Management and Postoperative Pain Outcomes: A Retrospective Study with Evidence-Based Recommendations
by
Amruta Desai, Shruti Parikh and Sergio Bergese
Int. J. Transl. Med. 2024, 4(3), 539-546; https://doi.org/10.3390/ijtm4030036 - 11 Aug 2024
Abstract
►▼
Show Figures
The prevalence of patients on buprenorphine therapy presenting for elective surgery has increased. Buprenorphine is a widely used medication for the management of patients with chronic pain. It is also used as maintenance therapy for patients with a history of opioid use disorder
[...] Read more.
The prevalence of patients on buprenorphine therapy presenting for elective surgery has increased. Buprenorphine is a widely used medication for the management of patients with chronic pain. It is also used as maintenance therapy for patients with a history of opioid use disorder (OUD). Due to the lack of a standardized protocol for managing patients on buprenorphine perioperatively, we performed a retrospective analysis to compare pain score outcomes and postoperative opiate requirements between patients who continued buprenorphine versus patients who discontinued buprenorphine. We identified 35 patients: 11 continued buprenorphine and 24 discontinued buprenorphine. The average Post-Anesthesia Care Unit (PACU) pain score was 5.59 for those who continued buprenorphine and 7.54 for those who discontinued preoperative buprenorphine (p value 0.0339). The average postoperative morphine milligram equivalent (MME) use was 86.13 for those who continued preoperative buprenorphine and 107.70 for those who discontinued buprenorphine (p value 0.6439). The results from our study correlate with several previous studies, which showed lower PACU pain scores in patients who continued buprenorphine. There is a benefit of decreased postoperative pain when preoperative buprenorphine is continued, and a decreased possibility for relapse in those with a history of OUD.
Full article
Figure 1
Open AccessArticle
Reduction of N-Acetylglucosaminyltransferase-I Activity Promotes Neuroblastoma Invasiveness and EGF-Stimulated Proliferation In Vitro
by
Adam P. Burch, M. Kristen Hall, Debra Wease and Ruth A. Schwalbe
Int. J. Transl. Med. 2024, 4(3), 519-538; https://doi.org/10.3390/ijtm4030035 - 6 Aug 2024
Abstract
►▼
Show Figures
Aberrant N-glycosylation has been associated with progression of the pediatric cancer neuroblastoma (NB) but remains understudied. Here we investigated oligomannose N-glycans in NB by genetic editing of MGAT1 in a human NB cell line, BE(2)-C, called BE(2)-C(MGAT1−/−). Lectin binding studies confirmed
[...] Read more.
Aberrant N-glycosylation has been associated with progression of the pediatric cancer neuroblastoma (NB) but remains understudied. Here we investigated oligomannose N-glycans in NB by genetic editing of MGAT1 in a human NB cell line, BE(2)-C, called BE(2)-C(MGAT1−/−). Lectin binding studies confirmed that BE(2)-C(MGAT1−/−) had decreased complex and increased oligomannose N-glycans. The relevance of 2D and 3D cell cultures was demonstrated for cell morphology, cell proliferation, and cell invasion, thereby highlighting the necessity for 3D cell culture in investigating cancerous properties. Western blotting revealed that oligomannosylated EGFR had increased autophosphorylation. Proliferation was decreased in BE(2)-C(MGAT1−/−) using 2D and 3D cultures, but both cell lines had similar proliferation rates using 3D cultures without serum. Upon EGF treatment, BE(2)-C(MGAT1−/−), but not BE(2)-C, showed increased proliferation, and furthermore, the mutant proliferated much faster than BE(2)-C under 3D conditions. Cell spheroid invasiveness was greatly increased in BE(2)-C(MGAT1−/−) compared with BE(2)-C. Moreover, invasiveness was reduced in both cell lines with either EGF or RhoA activator treatment, regardless of the N-glycan population. Thus, this study further extends our earlier findings that oligomannose N-glycans enhance NB cell invasiveness, and that EGF stimulation of oligomannosylated EGFR greatly enhances cell proliferation rates, underlining the role of oligomannose N-glycans in the promotion of NB.
Full article
Figure 1
Open AccessArticle
Photodynamic Therapy of Atherosclerotic Plaque Monitored by T1 and T2 Relaxation Times of Magnetic Resonance Imaging
by
Piotr Wańczura, David Aebisher, Dawid Leksa, Wiktoria Mytych, Klaudia Dynarowicz, Angelika Myśliwiec, Natalia Leksa, Adrian Truszkiewicz and Dorota Bartusik-Aebisher
Int. J. Transl. Med. 2024, 4(3), 505-518; https://doi.org/10.3390/ijtm4030034 - 5 Aug 2024
Abstract
►▼
Show Figures
Atherosclerosis, marked by plaque accumulation within arteries, results from lipid dysregulation, inflammation, and vascular remodeling. Plaque composition, including lipid-rich cores and fibrous caps, determines stability and vulnerability. Photodynamic therapy (PDT) has emerged as a promising treatment, leveraging photosensitizers to induce localized cytotoxicity upon
[...] Read more.
Atherosclerosis, marked by plaque accumulation within arteries, results from lipid dysregulation, inflammation, and vascular remodeling. Plaque composition, including lipid-rich cores and fibrous caps, determines stability and vulnerability. Photodynamic therapy (PDT) has emerged as a promising treatment, leveraging photosensitizers to induce localized cytotoxicity upon light activation. PDT targets plaque components selectively, reducing burden and inflammation. Challenges remain in optimizing PDT parameters and translating preclinical success to clinical efficacy. Nonetheless, PDT offers a minimally invasive strategy for atherosclerosis management, promising personalized interventions for cardiovascular health. The objective of the current study was to present the findings from quantitative non-contrast MRI of atherosclerosis post-PDT by assessing relaxation times. The study aimed to utilize and optimize a 1.5T MRI system. Clinical scanners were used for MRI examinations. The research involved analyzing T1 and T2 relaxation times. Following treatment of the samples with Rose Bengal and exposure to pure oxygen, PDT irradiation was administered. The results indicated that the therapy impacted the crus, evidenced by a significant decrease in relaxation times in the MRI data.
Full article
Figure 1
Open AccessArticle
Characteristics of 15 Subjects Affected by IgD Multiple Myeloma and the Key Role of the Laboratory in Diagnosis: A Retrospective Study Report and Literature Review
by
Jari Intra, Sara Pezzatti, Rinaldo Brivio, Monica Carpenedo, Rita Romano, Nadia Spinoni and Marco Casati
Int. J. Transl. Med. 2024, 4(3), 498-504; https://doi.org/10.3390/ijtm4030033 - 25 Jul 2024
Abstract
Immunoglobulin D (IgD) myeloma represents an uncommon subtype of multiple myeloma (MM), accounting for 1–2% of cases. Subjects affected by IgD MM have been demonstrated to have an inferior outcome and survival compared to those with other MM subtypes. A retrospective study was
[...] Read more.
Immunoglobulin D (IgD) myeloma represents an uncommon subtype of multiple myeloma (MM), accounting for 1–2% of cases. Subjects affected by IgD MM have been demonstrated to have an inferior outcome and survival compared to those with other MM subtypes. A retrospective study was conducted on 15 patients (9 males and 6 females) diagnosed from 2008 to 2022 with IgD MM, in order to investigate the clinical and biochemical features at the moment of diagnosis, cytogenetic alterations, and survival times. The median age was 69 years, and higher frequencies of bone lesions, renal impairments, Bence–Jones proteinuria, and increased serum LDH were observed. Serum calcium levels were in the reference ranges. In the assessment of protein electrophoresis patterns, nine patients had a serum monoclonal protein that was not detectable. A cytogenetic analysis via fluorescence in situ demonstrated that the most common abnormalities were the deletion of 13q and IGH rearrangements. Patients treated with new chemotherapeutic drugs (immunomodulators, proteasome inhibitors), with or without autologous stem cell transplantation presented a higher median survival. The fundamental role of the laboratory in monoclonal IgD detection and the monitoring and studying of IgD MM cases enhances the knowledge of this disease, thus improving patient outcomes.
Full article
Open AccessArticle
Organic Dust Exposure Enhances SARS-CoV-2 Entry in a PKCα- and ADAM-17-Dependent Manner
by
Abenaya Muralidharan, Christopher D. Bauer, Claire G. Nissen, St Patrick Reid, Jill A. Poole and Todd A. Wyatt
Int. J. Transl. Med. 2024, 4(3), 486-497; https://doi.org/10.3390/ijtm4030032 - 18 Jul 2024
Abstract
►▼
Show Figures
SARS-CoV-2, the causative agent of the COVID-19 pandemic, has had a global impact, affecting millions over the last three years. Pre-existing lung diseases adversely affect the prognosis of infected COVID-19 patients, and agricultural workers routinely exposed to inhalable organic dusts have substantial increased
[...] Read more.
SARS-CoV-2, the causative agent of the COVID-19 pandemic, has had a global impact, affecting millions over the last three years. Pre-existing lung diseases adversely affect the prognosis of infected COVID-19 patients, and agricultural workers routinely exposed to inhalable organic dusts have substantial increased risk for developing chronic lung diseases. In previous studies, we characterized the protein kinase C (PKC)-dependent airway inflammation mediated by organic dust extract (ODE) derived from dust collected from swine confinement facilities in in vitro and in vivo models. Here, we studied the effect of ODE on SARS-CoV-2 pseudoviral infection in mice and human bronchial epithelial cells (BEAS-2B). In wild-type (WT) and transgenic mice expressing the human angiotensin I-converting enzyme 2 (ACE2) receptor (SARS-CoV-2 entry receptor), ODE increased ACE2 shedding by ADAM-17 in the lungs. After repeated ODE treatments, the increased soluble ACE2 correlated to higher pseudovirus titer in the mouse lungs. In the human bronchial epithelial cells, ODE augmented PKCα activity in WT cells, and membrane ACE2 expression was diminished in PKCα-dominant negative cells. Unlike in the mice, increasing membrane ACE2 levels by treating with PKCα or ADAM-17 inhibitors and a low dose of ODE enhanced pseudoviral entry in vitro. Following viral entry, IL-8 secretion by the cells was diminished in a PKCα- and ADAM-17-independent manner. Together, the complex mechanisms involved in the synergistic effects of agricultural dust and SARS-CoV-2 highlight the importance of studying dust-mediated changes to immunity against circulating pathogens.
Full article
Figure 1
Open AccessReview
Targeting Cancer Stem Cells with Radioimmunotherapy: The Case of the Ovarian Cancer Stemness-Associated Biomarker L1CAM
by
Tihomir Zh. Todorov, Roger Schibli, Martin Béhé and Jürgen Grünberg
Int. J. Transl. Med. 2024, 4(3), 463-485; https://doi.org/10.3390/ijtm4030031 - 18 Jul 2024
Abstract
►▼
Show Figures
Cancer stem cells (CSCs) are a dynamic population of tumor cells characterized by long-term self-renewal, high tumorigenicity, resistance to conventional therapies such as radio- and chemotherapy, and capacity to recapitulate the tumor heterogeneity. Similar to other tumor cells, CSCs need to carry critical
[...] Read more.
Cancer stem cells (CSCs) are a dynamic population of tumor cells characterized by long-term self-renewal, high tumorigenicity, resistance to conventional therapies such as radio- and chemotherapy, and capacity to recapitulate the tumor heterogeneity. Similar to other tumor cells, CSCs need to carry critical mutations and epigenetic changes to acquire their aberrant phenotype. Confirmed in various hematologic and solid malignancies, the critical need to deepen our understanding of CSC biology, including identification of CSC biomarkers, and develop novel CSC-targeted therapies has been clearly recognized. Here, we review the L1 cell adhesion molecule (L1CAM) as a CSC-associated biomarker in ovarian cancer. Furthermore, we inform on the promising potential of anti-L1CAM radioimmunotherapy with 161Tb as a novel CSC-targeted therapeutic approach to overcome CSC radioresistance in comparison to 177Lu.
Full article
Figure 1
Open AccessReview
Epigenetic and Mental Diseases: The Role of Psychotherapy
by
Leonardo Massoni
Int. J. Transl. Med. 2024, 4(3), 450-462; https://doi.org/10.3390/ijtm4030030 - 11 Jul 2024
Abstract
It is well known that mental illness is often the result of genetic susceptibility combined with environmental factors. In this context, it is useful to consider the role that changes in DNA expression, known as epigenetic, can play in the development and progression
[...] Read more.
It is well known that mental illness is often the result of genetic susceptibility combined with environmental factors. In this context, it is useful to consider the role that changes in DNA expression, known as epigenetic, can play in the development and progression of psychiatric disorders. Accordingly, psychotherapy, a form of pharmacological strategy that often targets dysfunctional emotions and behaviors, may also improve the symptoms of mental illness via epigenetic changes. This article reviews the current literature on epigenetic changes induced by psychotherapy in psychiatric disorders, pointing out encouraging findings for borderline personality disorder (BPD), post-traumatic stress disorder (PTSD), anxiety disorders and obsessive–compulsive disorder (OCD). It focuses on genes that are more commonly associated with epigenetic changes and paves the way for further research.
Full article
Open AccessArticle
Serum-Derived Macrophage-Activating Factor Exhibits Anti-Tumor Activity via M2-to-M1 Macrophage Reprogramming
by
Tsuyoshi Takara, Rei Takara, Aya Kobayashi, Hina Shirakata, Shinobu Ambai, Yusei Shinohara and Yoshihiro Uto
Int. J. Transl. Med. 2024, 4(3), 439-449; https://doi.org/10.3390/ijtm4030029 - 30 Jun 2024
Abstract
►▼
Show Figures
Many anti-tumor effects of group-specific component-derived macrophage-activating factors (GcMAFs) have been reported; however, the specific mechanisms remain unclear. Controlling tumor-associated macrophages (TAMs) in the tumor microenvironment is essential for cancer treatment. This study assessed the role of GcMAF in macrophage activation, elucidated the
[...] Read more.
Many anti-tumor effects of group-specific component-derived macrophage-activating factors (GcMAFs) have been reported; however, the specific mechanisms remain unclear. Controlling tumor-associated macrophages (TAMs) in the tumor microenvironment is essential for cancer treatment. This study assessed the role of GcMAF in macrophage activation, elucidated the mechanisms by which it exerts its anti-tumor effects, and determined its effects on TAMs in the tumor microenvironment. GcMAF-stimulated RAW264.7 macrophages and EMT6 breast tumor cells were co-cultured in a 0.4 µm pore cell culture insert, and gene and protein expression and cell viability were evaluated. DNA microarray analysis of GcMAF-stimulated RAW264.7 cells was conducted. The induction of M2 RAW264.7 cells by interleukin (IL)-4 and IL-13 was analyzed. GcMAF stimulation increased the tumor necrosis factor-α and inducible nitric oxide synthase mRNA and protein levels in RAW264.7 cells but decreased the viability of co-cultured EMT6 cells. Although the details of the receptor or signal pathway of GcMAF are still unclear, these results were confirmed in the M2 RAW264.7 cells, suggesting that GcMAF exerts anti-tumor effects by inducing the differentiation of macrophages into the M1 type and reprogramming M2 macrophages to the M1 type. The anti-tumor activity of GcMAF via M2-to-M1 macrophage reprogramming could aid in developing novel cancer immunotherapies.
Full article
Figure 1
Open AccessReview
Dual Role of Tissue Factor Pathway Inhibitor 2—A Novel Serodiagnostic Marker for Ovarian Cancer—In Human Cancers
by
Hiroshi Kobayashi, Shogo Imanaka, Sho Matsubara, Hiroshi Shigetomi and Chiharu Yoshimoto
Int. J. Transl. Med. 2024, 4(3), 419-438; https://doi.org/10.3390/ijtm4030028 - 28 Jun 2024
Abstract
►▼
Show Figures
Background: Tissue factor pathway inhibitors (TFPI1 and TFPI2) are ubiquitously distributed in humans and exhibit inhibitory activity against serine proteinases. TFPI1 inhibits the tissue factor (TF)-dependent extrinsic coagulation pathway, while TFPI2 modulates extracellular matrix remodeling. TFPI2 has been reported to be an epigenetically
[...] Read more.
Background: Tissue factor pathway inhibitors (TFPI1 and TFPI2) are ubiquitously distributed in humans and exhibit inhibitory activity against serine proteinases. TFPI1 inhibits the tissue factor (TF)-dependent extrinsic coagulation pathway, while TFPI2 modulates extracellular matrix remodeling. TFPI2 has been reported to be an epigenetically silenced tumor suppressor and independent prognostic factor in various human cancers. However, elevated serum levels of TFPI2 have been observed in ovarian and endometrial cancers compared to healthy controls, with increased levels correlating with poor prognosis in endometrial cancer. This raises the question of why the tumor suppressor TFPI2 is elevated in the blood of patients with gynecological cancers and is associated with adverse outcomes. Methods: A comprehensive literature search was performed in PubMed and Google Scholar without time restriction. Results: TFPI2 gene expression may be influenced by both cancer cell-specific gene expression profiles (e.g., oncogenic signaling pathways) and epigenetic modifications (e.g., DNA methylation, histone modifications, and non-coding RNAs). Although TFPI2 generally exhibits an anti-invasion effect in most human cancers, it has been reported to have a paradoxical pro-invasive effect in certain cancers. TFPI2 facilitates cancer invasion through aberrant alternative splicing or through a pathophysiological process known as angiotropism or vasculogenic mimicry. The overproduction of TFPI2 in the tumor microenvironment may reinforce the extracellular matrix, thereby enhancing tumor cell adhesion and invasion. Conclusion: This review summarizes the current understanding of the seemingly contradictory functions of TFPI2 in human malignancies, primarily focusing on the mechanisms regulating its expression and function, and discusses future prospects for translational research.
Full article
Figure 1
Open AccessReview
Future Therapeutics: Targeting the NLRP3 Inflammasome Pathway to Manage Diabetic Retinopathy Development and Progression
by
Charisse Y. J. Kuo, Ilva D. Rupenthal, Rinki Murphy and Odunayo O. Mugisho
Int. J. Transl. Med. 2024, 4(3), 402-418; https://doi.org/10.3390/ijtm4030027 - 24 Jun 2024
Abstract
►▼
Show Figures
While existing local therapies partially restore vision loss from diabetic retinopathy (DR), there is currently no reliable treatment to prevent the onset or stop the progression of the disease. This review seeks to explore the inflammatory molecular mechanisms underpinning DR pathogenesis, which have
[...] Read more.
While existing local therapies partially restore vision loss from diabetic retinopathy (DR), there is currently no reliable treatment to prevent the onset or stop the progression of the disease. This review seeks to explore the inflammatory molecular mechanisms underpinning DR pathogenesis, which have not been targeted by current interventions. Specifically, this review explores the role of the nucleotide-binding oligomerization domain (NOD)-like receptor (NLR) protein 3 (NLRP3) inflammasome in DR onset and progression. Evidence through clinical trials has begun to note that specific drugs (fenofibrate, metformin) appear effective in slowing DR progression independent of lipid or glucose-lowering, respectively, suggesting that other mechanisms are at play. Novel therapeutics that inhibit the activation of the NLRP3 inflammasome pathway may provide a novel treatment for halting DR progression.
Full article
Figure 1
Highly Accessed Articles
Latest Books
E-Mail Alert
News
Topics
Topic in
Biomedicines, Brain Sciences, CIMB, Diagnostics, IJMS, IJTM
Autism: Molecular Bases, Diagnosis and Therapies, 2nd Volume
Topic Editors: Lello Zolla, Kunio YuiDeadline: 31 May 2025
Conferences
Special Issues
Topical Collections
Topical Collection in
IJTM
Feature Papers in International Journal of Translational Medicine
Collection Editor: Joan Oliva